Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Please provide your email address to receive an email when new articles are posted on . Prescriptions dispensed for apixaban beyond 90 days after hospitalization resulted in a lower rate of ...

The long-term adverse effects of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, are well ...

ORLANDO -- Researchers identified four predictors of clinically relevant bleeding in patients receiving extended anticoagulation with apixaban (Eliquis) for cancer-associated venous thromboembolism ...

The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...

Bologna 8 April 2022 - Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated ...